ACET

Adicet Bio Inc

May 15 • 04:00PM ET

7.68

-0.73 -8.68 %

Healthcare • Biotechnology • USA • Micro • NASD

Index	-	P/E	-	EPS (ttm)	-15.03	Insider Own	11.92%	Shs Outstand	9.60M	Perf Week	-10.18%
Market Cap	71.79M	Forward P/E	-	EPS next Y	-3.67	Insider Trans	11.95%	Shs Float	8.23M	Perf Month	-4.60%
Enterprise Value	-51.90M	PEG	-	EPS next Q	-2.18	Inst Own	57.59%	Short Float	6.73%	Perf Quarter	11.14%
Income	-108.83M	P/S	-	EPS this Y	50.80%	Inst Trans	27.64%	Short Ratio	4.40	Perf Half Y	-30.08%
Sales	0.00M	P/B	0.53	EPS next Y	55.97%	ROA	-60.35%	Short Interest	0.55M	Perf YTD	-8.79%
Book/sh	14.59	P/C	0.52	EPS next 5Y	-	ROE	-72.19%	52W High	17.44 -55.96%	Perf Year	-24.76%
Cash/sh	14.72	P/FCF	-	EPS past 3/5Y	14.57% 26.71%	ROIC	-72.03%	52W Low	6.01 27.79%	Perf 3Y	-93.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.94% 6.27%	Perf 5Y	-96.42%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	27.27%	Oper. Margin	-	ATR (14)	0.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	61.99%	SMA20	-5.47%	Beta	1.52	Target Price	34.83
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	2.92%	Rel Volume	1.10	Prev Close	8.41
Employees	102	LT Debt/Eq	0.08	Earnings	May 13 AMC	SMA200	-20.06%	Avg Volume	125.68K	Price	7.68
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	38.88% -	Trades		Volume	138,825	Change	-8.68%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-26	Resumed	Jefferies	Buy	$19
Sep-30-24	Resumed	Guggenheim	Buy	$7
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral	$20 → $6
Sep-21-22	Initiated	JP Morgan	Overweight	$23
Mar-31-22	Initiated	SMBC Nikko	Outperform	$28
Mar-08-22	Initiated	Truist	Buy	$30
Mar-04-22	Initiated	Jefferies	Buy	$27
May-18-21	Initiated	BTIG Research	Buy	$34
Apr-23-21	Initiated	H.C. Wainwright	Buy	$27
Apr-14-21	Initiated	Canaccord Genuity	Buy	$28
Apr-08-21	Initiated	Guggenheim	Buy	$22
Nov-04-20	Initiated	B. Riley Securities	Buy	$30
Oct-27-20	Initiated	JMP Securities	Mkt Outperform	$30
Oct-16-20	Initiated	Wedbush	Outperform	$25

Show Previous Ratings

May-14-26 04:00PM	Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference (Business Wire) -8.68%
May-13-26 04:01PM	Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Mar-12-26 04:00PM	Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress (Business Wire) -5.76%
Jan-30-26 07:00AM	Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -6.00%
Jan-07-26 07:00AM	Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones (Business Wire)
08:30AM	Loading…
Dec-26-25 08:30AM	Adicet Bio Announces Reverse Stock Split (Business Wire)
Nov-28-25 02:23PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.85%
Nov-05-25 04:01PM	Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-31-25 04:59PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-28-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -5.12%
Oct-16-25 07:00AM	Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) (Business Wire) +5.49%
Oct-07-25 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks) -14.69%
07:01AM	Adicet Bio, Inc. Announces $80 Million Registered Direct Offering (Business Wire)
06:45AM	Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (Business Wire)
Sep-30-25 04:27PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Loading…
12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-02-25 07:00AM	Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-29-25 04:48PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.09%
Aug-12-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's Why (Zacks) +7.14%
Aug-07-25 04:01PM	Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.62%
Aug-06-25 04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference (Business Wire)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-25-25 07:27AM	Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 (Clinical Trials Arena)
Jul-24-25 07:00AM	Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
May-21-25 04:00PM	Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference (Business Wire) -6.59%
May-09-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks) +27.49%
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.44% -18.65%
Apr-30-25 04:47PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.41% -5.07%
07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
04:30PM	Loading…
Apr-28-25 04:30PM	Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire) +5.82%
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire) -7.96%
Mar-31-25 05:12PM	Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.06%
07:00AM	Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Mar-23-25 08:43AM	Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-24 05:19PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:35AM	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +7.35%
Mar-19-24 09:53PM	ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 (InvestorPlace) +5.42%
04:10PM	Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Mar-15-24 09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Mar-11-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 07:46PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 09:40AM	Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-05-24 04:01PM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-31-24 04:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-30-24 12:51PM	Hedge Fund and Insider Trading News: Larry Robbins, Ray Dalio, Two Sigma Investments, Point72 Asset Management, Bluebell Capital Partners, Adicet Bio Inc (ACET), Netflix, Inc. (NFLX), and More (Insider Monkey)
Jan-25-24 04:01PM	Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire)

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

CPAMr. Chen Schor BA

Senior VP & Chief Scientific OfficerDr. Blake Aftab Ph.D.

Chief Medical OfficerDr. Julie Maltzman M.D.

Chief Financial OfficerMr. Brian Nicholas Harvey M.B.A.

Chief Technology OfficerDr. Donald Healey Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 20 '26	Buy	7.27	74,751	543,440	1,182,624	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 19 '26	Buy	7.21	74,268	535,472	1,107,873	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 18 '26	Buy	7.04	74,577	525,022	1,033,605	Apr 13 05:20 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 08 '26	Sale	6.42	72,939	468,082	0	Apr 09 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 07 '26	Sale	6.52	31,719	206,765	32,523	Apr 09 05:38 PM
OrbiMed Genesis Master Fund, L	Shareholder	Apr 09 '26	Proposed Sale	6.55	78,499	514,168		Apr 09 05:34 PM
OrbiMed Israel Partners II, L.	Shareholder	Apr 08 '26	Proposed Sale	6.55	40,416	264,725		Apr 08 08:14 PM
OrbiMed Israel Partners Limite	Shareholder	Apr 07 '26	Proposed Sale	6.43	64,242	413,076		Apr 07 08:46 PM
ORBIMED ADVISORS LLC	10% Owner	Oct 08 '25	Buy	1.00	5,000,000	5,000,000	9,026,359	Oct 10 08:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your Finviz experience